相关实验视频
Updated: Jun 14, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.8K
在心脏性休克的背景下,SGLT-2i相关的糖尿病酸症
Alex Guzner1, Ian Downs2, Daniel Cruz3
1Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, California, USA.
BMJ case reports
|September 6, 2024
概括
-葡萄糖联合输送抑制剂 (SGLT-2i) 可以增加糖尿病酸性脂肪酸症 (DKA) 的风险,特别是在心力衰竭患者中. 这一案例强调了在这些人中,在与心脏性休克一起管理DKA时,需要特别考虑.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病酸症 (DKA) 是糖尿病的一种严重并发症.
- -葡萄糖联合输送抑制剂 (SGLT-2i) 改善了心力衰竭的结果,减少了喷射分数 (HFrEF).
- 患有HFrEF的患者越来越多地接受SGLT-2i治疗,有时可以替代胰岛素治疗.
研究的目的:
- 报告同时发生心脏性休克和DKA的病例.
- 要强调DKA在SGLT-2i的HFrEF患者中新出现的挑战.
- 突出这一患者群体的独特管理考虑因素.
主要方法:
- 案例报告的呈现方式.
- 对临床表现和管理的审查.
- 在HFrEF中讨论SGLT-2i与DKA的关联.
主要成果:
- 一名患有HFrEF的患者,最近从胰岛素转换为SGLT-2i,同时出现心脏性休克和DKA.
- 这种临床情景强调了SGLT-2i.在HFrEF患者中DKA的潜力.
结论:
- 与无补偿性心力衰竭并发的DKA预计将随着HFrEF中SGLT-2i的更广泛使用而增加.
- 在这些患者中,对DKA的管理需要对体积状态,和识别采取不同的方法.
- 早期识别和专业管理对于有利的结果至关重要.
相关概念视频
Oral Hypoglycemic Agents: Glinides
148
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
148
Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178
Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306
Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183
Glucose Transporters
22.6K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.6K
Oral Hypoglycemic Agents: Sulfonylureas
197
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
197

